Oxidative stress and inflammation: Implications in uremia and hemodialysis

Clinical Biochemistry

Volumn 44, Issue 14-15, 2011, Pages 1189-1198

  Libetta, Carmelo ^a   Sepe, Vincenzo ^a   Esposito, Pasquale ^a   Galli, Francesco ^b   Dal Canton, Antonio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Acute kidney injury; Chronic kidney disease; Hemodialysis; Oxidative stress; Reactive nitrogen species; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; AMINOPHYLLINE; ANTIOXIDANT; ASCORBIC ACID; CATALASE; CYANOCOBALAMIN; CYTOKINE; ELASTASE; FOLIC ACID; FREE RADICAL; GAMMA TOCOPHEROL; GLUTATHIONE; HOMOCYSTEINE; LIPOPROTEIN; MALONALDEHYDE; MELATONIN; MYELOPEROXIDASE; NORPHENAZONE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; PYRIDOXINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TEMPOL; THEOPHYLLINE; THROMBOCYTE ACTIVATING FACTOR;

ACUTE KIDNEY FAILURE; ANTIINFLAMMATORY ACTIVITY; BIOCOMPATIBILITY; BIOINCOMPATIBILITY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTRAST INDUCED NEPHROPATHY; CYTOKINE PRODUCTION; DIALYSIS MEMBRANE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; INFLAMMATION; KIDNEY FAILURE; KIDNEY ISCHEMIA; LIPID PEROXIDATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RENAL PROTECTION; REPERFUSION INJURY; REVIEW; TREATMENT OUTCOME; UREMIA;

ACUTE KIDNEY INJURY; ANTIOXIDANTS; FREE RADICALS; HUMANS; INFLAMMATION; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS; RENAL DIALYSIS; UREMIA;

EID: 80052921322     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.06.988     Document Type: Review

References (114)

1. Halliwell B., Gutteridge J.M.C. Free radicals in biology and medicine 1999, Oxford University Press, Oxford. Ed. 3.
2. Diplock A.T., Chaleux J.L., Crozier-Willi G., Kok F.S., Rice-Evans C., Roberfroid M., et al. Functional food sciences and defenses against reactive oxygen species. Br J Nutr 1998, 80:S77-S112.
3. Romano A.D., Serviddio G., de Matthaeis A., Bellanti F., Vendemiale G. Oxidative stress and aging. J Nephrol 2010, 23:S29-S36.
4. Robinson J.M. Phagocytic leukocytes and reactive oxygen species. Histochem Cell Biol 2009, 131:465-469.
5. Yamakura F., Kawasaki H. Post-translational modifications of superoxide dismutase. Biochim Biophys Acta 2010, 1804(2):318-325.
6. Lynch S.M., Frei B. Physiological thiols compounds exert pro- and anti-oxidant effects, respectively, on iron and copper dependent oxidation of human low density lipoproteins. BBA 1997, 1345:215-221.
7. Hasselwander O., Young I.S. Oxidative stress in chronic renal failure. Free Radic Res 1998, 29(1):1-11.
8. Ceballos-Picot I., Witko-Sarsat V., Merad-Boudia M., Nguyen A.T., Thévenin M., Jaudon M.C., et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996, 21:845-853.
9. Kim H.J., Vaziri N.D. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 2010, 298:F662-F671.
10. Galli F., Rovidati S., Benedetti S., Canestrari F., Ferraro B., Floridi A., et al. Lipid peroxidation, leucocyte function and apoptosis in HD patients treated with vitamin E-modified filters. Contrib Nephrol 1999, 127:156-171.
11. Miyata T., van Ypersele C., Kurokawa K., Baynes J.W. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl-stress" in long-term uremic complications. Kidney Int 1999, 55:389-399.
12. Klahr S. Oxygen radicals and renal diseases. Miner Electrolyte Metab 1997, 23:140-143.
13. Vaziri N.D. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol 2004, 24(5):469-473.
14. Lee H.S., Song C.Y. Oxidized low-density lipoprotein and oxidative stress in the development of glomerulosclerosis. Am J Nephrol 2009, 29(1):62-70.
15. Cochrane A.L., Ricardo S.D. Oxidant stress and regulation of chemokines in the development of renal interstitial fibrosis. Contrib Nephrol 2003, 139:102-119.
16. Dobashi K., Ghosh B., Orak J.K., Singh I., Singh A.K. Kidney ischemia-reperfusion: modulation of antioxidant defenses. Mol Cell Biochem 2000, 205:1-11.
17. Hannken T., Schroeder R., Zahner G., Stahl R.A.K., Wolf G. Reactive oxygen species stimulate p44/42 mitogen-activated protein kinase and induce p27Kip1: role in angiotensin II-mediated hypertrophy of proximal tubular cells. J Am Soc Nephrol 2000, 11:1387-1397.
18. Bellomo R., Auriemma S., Fabbri A., D'Onofrio A., Katz N., McCullough P.A., et al. The pathophysiology of cardiac surgery-associated acute kidney injury (CSA-AKI). Int J Artif Organs 2008, 31(2):166-178.
19. Himmelfarb J., McMonagle E., Freedman S., Klenzak J., McMenamin E., Le P., et al. The PICARD group, oxidative stress is increased in critically ill patients with acute renal failure. J Am Soc Nephrol 2004, 15(9):2449-2456.
20. Akcay A., Nguyen Q., Edelstein C.L. Mediators of inflammation in acute kidney injury. Mediators Inflamm 2009, 137072.
21. Trachtman H., Chan J.C., Chan W., Valderrama E., Brandt R., Wakely P., et al. Vitamin E ameliorates renal injury in an experimental model of immunoglobulin A nephropathy. Pediatr Res 1996, 40(4):620-626.
22. Quiroz Y., Ferrebuz A., Vaziri N.D., Rodriguez-Iturbe B. Effect of chronic antioxidant therapy with superoxide dismutase-mimetic drug, tempol, on progression of renal disease in rats with renal mass reduction. Nephron Exp Nephrol 2009, 112(1):e31-e42.
23. Lloberas N., Torras J., Herrero-Fresneda I., Cruzado J.M., Riera M., Hurtado I., et al. Postischemic renal oxidative stress induces inflammatory response through PAF and oxidized phospholipids. Prevention by antioxidant treatment. FASEB J 2002, 16:908-910.
24. Doi K., Suzuki Y., Nakao A., Fujita T., Noiri E. Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney. Kidney Int 2004, 65:1714-1723.
25. DiBowa G.F., McDonald F.D., Flamenbaum W., Dammin G.J., Oken D.E. Maintenance of renal function in salt loaded rats despite severe tubular necrosis induced by HgCl2. Nephron 1971, 8:205-220.
26. Thiel G., Brunner F., Wunderlich P., Huguennin M., Bienko B., Torhorst J., et al. Protection of rat kidney HgCl2-induced acute renal failure by induction of high urine flow without renin suppression. Kidney Int 1976, 10:S191-S200.
27. Molina A., Sánchez-Madrid F., Bricio T., Martín A., Escudero E., Alvarez V., et al. Abrogation of mercuric chloride-induced nephritis in the Brown Norway rat by treatment with antibodies against TNFα. Mediators Inflamm 1995, 4(6):444-451.
28. de Ceaurriz J., Payan J.P., Morel G., Brondeau M.T. Role of extracellular glutathione and gamma-glutamyltranspeptidase in the disposition and kidney toxicity of inorganic mercury in rats. J Appl Toxicol 1994, 14:201-206.
29. Weinberg J.M., Harding P.G., Humes H.D. Mitochondrial bioenergetics during the initiation of mercuric chloride-induced renal injury II. Functional alterations of renal cortical mitochondria isolated after mercuric chloride treatment. J Biol Chem 1982, 257:68-74.
30. De Lastra C.A., Cabeza J., Motilva V., Martín M.J. Melatonin protects against gastric ischemia-reperfusion injury in rats. J Pineal Res 1997, 23:47-52.
31. Zhou L., Wei W., Si J., Dong-ping Y. Regulatory effect of melatonin on cytokine disturbances in the pristane-induced lupus mice. Mediators Inflamm 2010, pii:951210.
32. Montilla P., Tunez I., Muñoz M.C., Lopez A., Soria J.V. Hyperlipidemic nephropathy induced by adriamycin: effect of melatonin administration. Nephron 1997, 76:345-350.
33. Nava M., Romero F., Quiroz Y., Parra G., Bonet L., Rodriguez-Iturbe B. Melatonin attenuates acute renal failure and oxidative stress induced by mercuric chloride in rats. Am J Physiol Renal Physiol 2000, 279:F910-F918.
34. Baliga R., Ueda N., Walker P.D., Shah S.V. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 1999, 31:971-997.
35. Singh D., Chander V., Chopra K. Carvedilol, an antihypertensive drug with antioxidant properties, protects against glycerol-induced acute renal failure. Am J Nephrol 2003, 23:415-521.
36. Parfrey P.S., Griffiths S.M., Barrett B.J., Paul M.D., Genge M., Withers J., et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. N Engl J Med 1989, 320:143-149.
37. Rudnick M.R., Goldfarb S., Wexler L., Ludbrook P.A., Murphy M.J., Halpern E.F., et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial: the Iohexol Cooperative Study. Kidney Int 1995, 47:254-261.
38. Kurnik B.R., Allgren R.L., Genter F.C., Solomon R.J., Bates E.R., Weisberg L.S. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998, 31:674-680.
39. Hans S.S., Hans B.A., Dhillon R., Dmuchowski C., Glover J. Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. Am Surg 1998, 64:432-436.
40. Yoshioka T., Fogo A., Beckman J.K. Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 1992, 41:1008-1015.
41. Bakris G.L., Lass N., Gaber A.O., Jones J.D., Burnett J.C. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol 1990, 258:F115-F120.
42. Aruoma O.I., Halliwell B., Hoey B.M., Butler J. The antioxidant action of N-acetylcysteine: Its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989, 6:593-597.
43. Ferrari R., Ceconi C., Curello S., Cargnoni A., Alfieri O., Pardini A., et al. Oxygen free radicals and myocardial damage: protective role of thiol-containing agents. Am J Med 1991, 91:S95-S105.
44. Tepel M., van der Giet M., Schwarzfeld C., Laufer U., Liermann D., Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000, 343:180-184.
45. Amini M., Salarifar M., Amirbaigloo A., Masoudkabir F., Esfahani F. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial. Trials 2009, 10:45.
46. Fishbane S. N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol 2008, 3:281-287.
47. Arend L.J., Bakris J.L., Burnett J.C., Megerian C., Spielman W.S. Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med 1987, 110:406-411.
48. Xia Y., Khatchikian G., Zweier J.L. Adenosine deaminase inhibition prevents free radical-mediated injury in the postischemic heart. J Biol Chem 1996, 271:10096-10102.
49. Erley C.M., Duda S.H., Schlepckow S., Koehler J., Huppert P.E.P. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 1994, 45:1425-1431.
50. Lapenna D., De Gioia S., Mezzetti A., Ciofani G., Festi D., Cuccurullo F. Aminophylline: could it act as an antioxidant in vivo?. Eur J Clin Invest 1995, 25:464-470.
51. Williams D.F. A model for biocompatibility and its evolution. J Biomed Eng 1989, 11:185-191.
52. Kaplow L.S., Goffinet J.A. Profund neutropenia during the early phase of hemodialysis. JAMA 1968, 203:1135-1137.
53. Craddock P.R., Fehr J., Brigham K.L., Kronenberg R.S., Jacob H.S. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med 1977, 296:769-774.
54. Chenoweth D.E., Cheung A.K., Henderson L.W. Anaphylatoxin formation during hemodialysis: effects of different dialyzer membranes. Kidney Int 1993, 24:764-769.
55. Fischer W.H., Jagels M.A., Hugli T.E. TE, regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(desArg). J Immunol 1999, 162:453-459.
56. Memoli B., Libetta C., Rampino T., Dal Canton A., Conte G., Scal G., et al. Hemodialysis related induction of interleukin-6 production by peripheral blood mononuclear cells. Kidney Int 1992, 42:320-326.
57. Lonnemann G., Van Der Meer J.W.M., Cannon J.G., Dinarello C., Koch K.M., Granolleras C., et al. Induction of tumor necrosis factor during extracorporeal blood purification. N Engl J Med 1987, 317:963-964.
58. Borazan A., Ustün H., Ustundag Y., Aydemir S., Bayraktaroglu T., Sert M., et al. The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels. Mediators Inflamm 2004, 13:201-204.
59. Haeffner-Cavaillon N., Cavaillon J.M., Laude M., Kazatchkine M.D. MD, C3a (C3adesArg) induces production and release of interleukin 1 by cultured human monocytes. J Immunol 1987, 139:794-799.
60. Laude-Sharp M., Caroff M., Simard L., Pusineri C., Kazatchkine M.D., Haeffner-Cavaillon N. Induction of IL-1 during hemodialysis: Transmembrane passage of intact endotoxins (LPS). Kidney Int 1990, 38:1089-1094.
61. Betz M., Haensch G.M., Rauterberg E.W., Bommer J., Ritz E. Cuprammonium membranes stimulate interleukin-1 release and arachidonic acid metabolism in monocytes in the absence of complement. Kidney Int 1988, 34:67-73.
62. Gejyo F., Homma N., Arakawa K.M. Carpal tunnel syndrome and ß2-microglobulin related amyloidosis in chronic hemodialysis patients. Blood Purif 1988, 6:125-131.
63. Mailloux L.U., Bellucci A.G., Wilkes B.M. Mortality in dialysis patients: analysis of the cause of death. Am J Kidney Dis 1991, 3:326-335.
64. Dinarello C.A., Shaldon S. Hemodialysis hypotension: the interleukin hypotesis. Blood Purif 1983, 1:3-8.
65. Tarakçioǧlu M., Erbaǧci A.B., Usalan C., Deveci R., Kocabaş R. Acute effect of hemodialysis on serum levels of the proinflammatory cytokines. Mediators Inflamm 2003, 12:15-19.
66. Sanchez-Niño MD, Benito-Martin A, Gonçalves S, Sanz AB, Ucero AC, Izquierdo MC, et al. TNF superfamily: a growing saga of kidney injury modulators. Mediators Inflamm 2010;pii:182958.
67. Ritchie D.G., Fuller G.M. Hepatocyte-stimulating factor: a monocyte-derived acute-phase regulatory protein. Ann N Y Acad Sci 1983, 408:490-502.
68. Steel D.M., Whitehead A.S. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 1994, 15:81-88.
69. Herbelin A., Urena P., Nguyen A.T., Zingraff J., Descamps-Latscha B. Elevated circulating levels of IL-6 in patients with chronic renal failure. Kidney Int 1991, 39:954-960.
70. Libetta C., De Nicola L., Rampino T., De Simone W., Memoli B. Inflammatory effects of peritoneal dialysis: evidence of systemic monocyte activation. Kidney Int 1996, 49:506-511.
71. Yawata H., Yasukawa K., Natsuka S., Murakami M., Yamasaki K., Hibi M., et al. Structure-function analysis of human IL-6 receptor: dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130. EMBO J 1993, 12:1705-1712.
72. Memoli B., Libetta C., Rossi M., Saluzzi A., Bisesti V., Camocardi A., et al. Peripheral blood mononuclear cells production and plasma levels of soluble interleukin-6 receptor (sIL-6R) in chronic uremia. Blood Purif 1997, 1(5):47.
73. Borazan A., Aydemir S., Sert M., Yilmaz A. The effects of hemodialysis and peritoneal dialysis on serum homocysteine and C-reactive protein levels. Mediators Inflamm 2004, 13(5-6):361-364.
74. Nguyen-Khoa T., Massy Z.A., De Bandt J.P., Kebede M., Salama L., Lambrey G., et al. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001, 16:335-340.
75. Witko-Sarsat V., Friedlander M. Nguyen Khoa T, Capeillère-Blandin C, Nguyen AT, Canteloup S, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998, 161:2524-2532.
76. Zeller J.M., Sullivan B.L. C-reactive protein selectively enhances the intracellular generation of reactive oxygen products by IgG-stimulated monocytes and neutrophils. J Leukoc Biol 1992, 52(4):449-455.
77. Danielski M., Ikizler T.A., McMonagle E., Kane J.C., Pupim L., Morrow J., et al. Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am J Kidney Dis 2003, 42:286-294.
78. Schwedler S., Schinzel R., Vaith P., Wanner C. Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship?. Kidney Int 2001, 59:S32-S36.
79. Moradi H., Pahl M.V., Elahimehr R., Vaziri N.D. Impaired antioxidant activity of HDL in chronic kidney disease. Transl Res 2009, 153:77-85.
80. Feig J.E., Shamir R., Fisher E.A. Atheroprotective effects of HDL: beyond reverse cholesterol transport. Curr Drug Targets 2008, 9:196-203.
81. Vaziri N.D., Moradi H., Pahl M.V., Fogelman A.M., Navab M. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int 2009, 76:437-444.
82. Dursun B., Dursun E., Suleymanlar G., Ozben B., Capraz I., Apaydin A., et al. Carotid artery intima-media thickness correlates with oxidative stress in chronic haemodialysis patients with accelerated atherosclerosis. Nephrol Dial Transplant 2008, 23(5):1697-1703.
83. Stevens C.E., Alter M.D., Taylor P.E., Zang E.A., Harley E.J., Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis: immunogenicity and efficacy. N Engl J Med 1984, 311:496-500.
84. Raska K., Raskova J., Shea S.M., Frankel L.M., Wood R.H., Lifter J., et al. T cell subsets and cellular immunity in end stage renal disease. Am J Med 1983, 75:734-740.
85. Tsakolos N.D., Theoharides T.H.C., Hendler E.D., Goffinet J., Dwyer J.M., Whisler R.L., et al. Immune defect in chronic renal impairment: evidence for defective regulation of lymphocyte response by macrophages from patients with chronic renal impairment on hemodialysis. Clin Exp Immunol 1986, 63:218-227.
86. Robinson M.K., Rodrick M.L., Jacobs D.O., Rounds J.D., Collins K.H., Saporoschetz I.B., et al. Glutathione depletion in rats impairs T-cell and macrophage immune function. Arch Surg 1993, 128:29-34.
87. Peterson J.D., Herzenberg L.A., Vasquez K., Waltenbaugh C. Glutathione levels in antigen-presenting cellsmodulate Th1 versus Th2 response patterns. Proc Natl Acad Sci 1998, 95:3071-3076.
88. Galli F., Rovidati S., Chiarantini L., Campus G., Canestrari F., Buoncrisiani U. Bioreactivity and biocompatibility of a vitamin E-modified multi-layer hemodialysis filter. Kidney Int 1998, 54:580-589.
89. Cruz D.N., De Cal M., Garzotto F., Brendolan A., Nalesso D., Corradi V., et al. Effect of vitamin E-coated dialysis membranes on anemia in patients with chronic kidney disease: an Italian multicenter study. Int J Artif Organs 2008, 31(6):545-552.
90. Galli F., Rovidati S., Benedetti S., Canestrari F., Ferraro B., Floridi A., et al. Lipid peroxidation, leukocyte function and apoptosis in hemodialysis patients treated with vitamin-E modified filters. Contrib Nephrol 1999, 127:156-171.
91. Schiecke G., Gwinner W., Radermacher J., Bahlmann J., Lonnemann G. Long-term effect of vitamin E-bonded dialysis membrane on mononuclear cell activation, malondialdehyde generation and endothelial function in ESRD patients. Contrib Nephrol 1999, 127:243-250.
92. Tsuruoka S., Kawaguchi A., Nishiki K., Hayasaka T., Fukushima C., Sugimoto K., et al. Vitamin E-bonded hemodialyzer improves neutrophil function and oxidative stress in patients with end-stage renal failure. Am J Kidney Dis 2002, 39:127-133.
93. Girndt M., Lengler S., Kaul H., Sester U., Sester M., Kohler H. Prospective crossover trial of the influence of vitamin E-coated dialyzer membranes on T-cell activation and cytokine induction. Am J Kidney Dis 2000, 35:95-104.
94. Tarng D.C., Huang T.P., Liu T.Y., Chen H.W., Sung Y.J., Wei Y.H. Effect of vitamin E-bonded membrane on the 8-hydroxy 2'-deoxyguanosine level in leukocyte DNA of hemodialysis patients. Kidney Int 2000, 58:790-799.
95. Morimoto H., Nakao K., Fukuoka K., Sarai A., Yano A., Kihara T., et al. Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients. Nephrol Dial Transplant 2005, 20:2775-2782.
96. Libetta C., Rampino T., Dal Canton A. Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients. Am J Kidney Dis 2001, 38:286-295.
97. Galli F., Ronco C. Oxidant stress in hemodialysis. Nephron 2000, 84:1-5.
98. Libetta C., Zucchi M., Gori E., Sepe V., Galli F., Meloni F., et al. Vitamin E-loaded dialyzer resets PBMC-operated cytokine network in dialysis patients. Kidney Int 2004, 65:1473-1481.
99. Boaz M., Smetana S., Weinstein T., Matas Z., Gafter U., Iaina A., et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo controlled trial. Lancet 2000, 356:1213-1218.
100. Hensley K., Benaksas E.J., Bolli R., Comp P. New perspectives on vitamin E: gamma-tocopherol and carboxyethylhydroxychroman metabolites in biology and medicine. Free Radic Biol Med 2004, 3(6):115.
101. Himmelfarb J., Kane J., McMonagle E., Zaltas E., Bobzin S., Boddupalli S., et al. Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease. Kidney Int 2003, 64:978-991.
102. Hsu S.P., Chiang C.K., Yang S.Y., Chien C.T. N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients. Nephron Clin Pract 2010, 116(3):c207-c216.
103. Scholze A., Rinder C., Beige J., Riezler R., Zidek W., Zidek W., et al. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 2004, 109:369-374.
104. Tarng D.C., Huang T.P. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrol Dial Transplant 1998, 13:2867-2872.
105. Tarng D.C., Wei Y.H., Huang T.P., Kuo B.I., Yang W.C. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int 1999, 55:2477-2486.
106. Bienfait H.F., Van Den Briel M.L. Rapid mobilization of ferritin iron by ascorbate in the presence of oxygen. Biochim Biophys Acta 1980, 631:507-510.
107. Moradi H., Ganji S., Kamanna V.j., Pahl M.V., Vaziri N.D. Increased Monocyte adhesion-promoting capacity of plasma in end-stage renal disease - response to antioxidant therapy. Clin Nephrol 2010, 74(4):273-281.
108. Libetta C., Zucchi M., Gori E., Sepe V., Bezoari G., Dal Canton A. Prevalence of hyperhomocysteinemia in male hemodialysis patients. Kidney Int 2003, 6(4):1531.
109. Moustapha A., Naso A., Nahlawi M., Gupta A., Arheart K.L., Jacobsen D.W., et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998, 97:138-141.
110. Papatheodorou L., Weiss N. Vascular oxidant stress and inflammation in hyperhomocysteinemia. Antioxid Redox Signal 2007, 9(11):1941-1958.
111. Alvares Delfino V.D., de Andrade Vianna A.C., Mocelin A.J., Barbosa D.S., Mise R.A., Matsuo T. Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients. Nutrition 2007, 23(3):242-247.
112. Jamison R.L., Hartigan P., Kaufman J.S., Goldfarb D.S., Warren S.R., Guarino P.D., et al. Veterans Affairs Site Investigators, effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2008, 298(10):1163-1170. Erratum in: JAMA. 300(2):170.
113. Zoccali C., Mallamaci F., Tripepi G. It is important to lower homocysteine in dialysis patients. Semin Dial 2007, 20:530-533.
114. Heinz J., Kropf S., Luley C., Dierkes J. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis. Am J Kidney Dis 2009, 54(3):478-489.